MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 1013-1021

  Liu, Yanwei ^a   Yan, Wei ^a   Zhang, Wei ^a   Chen, Lingchao ^b   You, Gan ^a   Bao, Zhaoshi ^a   Wang, Yongzhi ^a   Wang, Hongjun ^b   Kang, Chunsheng ^c   Jiang, Tao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

GBM; Invasion; LEF1; miR 218; MMP 9; Wnt pathway

Indexed keywords

GELATINASE A; GELATINASE B; LYMPHOID ENHANCER FACTOR 1; MATRILYSIN; MESSENGER RNA; MICRORNA; MICRORNA 218; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE TARGETING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

BASE SEQUENCE; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASE 9; MICRORNAS; NEOPLASM INVASIVENESS; RNA INTERFERENCE; TISSUE ARRAY ANALYSIS;

EID: 84865320856     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1902     Document Type: Article

References (41)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Sameshima T, Nabeshima K, Toole BP, et al: Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett 157: 177-184, 2000.
3. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92: 827-839, 2003.
4. Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69: 562-573, 2006.
5. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27: 2575-2582, 2008.
6. Alajez NM, Lenarduzzi M, Ito E, et al: MiR-218 suppresses nasopharyngeal cancer progression through downregulation of survivin and the SLIT2-ROBO1 pathway. Cancer Res 71: 2381-2391, 2011.
7. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al: The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 18: 2883-2891, 1999.
8. Wu B, Crampton SP and Hughes CC: Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration. Immunity 26: 227-239, 2007.
9. Yan W, Zhang W, Sun L, et al: Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 1411: 108-115, 2011.
10. Zhang J, Han L, Zhang A, et al: AKT2 expression is associated with glioma malignant progression and required for cell survival and invasion. Oncol Rep 24: 65-72, 2010.
11. Birner P, Toumangelova-Uzeir K, Natchev S and Guentchev M: STAT3 tyrosine phosphorylation influences survival in glioblastoma. J Neurooncol 100: 339-343, 2010.
12. Wang Y, Chen L, Bao Z, et al: Inhibition of STAT3 reverses alkylator resistance through modulation of the AKT and beta-catenin signaling pathways. Oncol Rep 26: 1173-1180, 2011.
13. Debinski W and Gibo DM: Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 3: 237-249, 2005.
14. Zhou X, Ren Y, Moore L, et al: Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Lab Invest 90: 144-155, 2010.
15. Tie J, Pan Y, Zhao L, et al: MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet 6: e1000879, 2010.
16. Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
17. Rao SA, Santosh V and Somasundaram K: Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma. Mod Pathol 23: 1404-1417, 2010.
18. Silber J, Lim DA, Petritsch C, et al: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6: 14, 2008.
19. 2 levels. J Biol Chem 286: 17649-17657, 2011.
20. Collier IE, Legant W, Marmer B, et al: Diffusion of MMPs on the surface of collagen fibrils: the mobile cell surface-collagen substratum interface. PLoS One 6: e24029, 2011.
21. Uddin S, Hussain AR, Siraj AK, et al: Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108: 4178-4186, 2006.
22. Hou J, Lin L, Zhou W, et al: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19: 232-243, 2011.
23. Shi W, Gerster K, Alajez NM, et al: MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 71: 2926-2937, 2011.
24. Sun D, Lee YS, Malhotra A, et al: miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 71: 1313-1324, 2011.
25. Saydam O, Shen Y, Wurdinger T, et al: Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 29: 5923-5940, 2009.
26. Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033, 2005.
27. Maiese K, Li F, Chong ZZ and Shang YC: The Wnt signaling pathway: aging gracefully as a protectionist? Pharmacol Ther 118: 58-81, 2008.
28. He TC, Sparks AB, Rago C, et al: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
29. Shtutman M, Zhurinsky J, Simcha I, et al: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522-5527, 1999.
30. Li TW, Ting JH, Yokoyama NN, Bernstein A, van de Wetering M and Waterman ML: Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol Cell Biol 26: 5284-5299, 2006.
31. Lin AY, Chua MS, Choi YL, et al: Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS One 6: e16636, 2011.
32. Mei JM, Borchert GL, Donald SP and Phang JM: Matrix metalloproteinase(s) mediate(s) NO-induced dissociation of beta-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex. Carcinogenesis 23: 2119-2122, 2002.
33. Rivat C, Le Floch N, Sabbah M, et al: Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J 17: 1721-1723, 2003.
34. Kriegl L, Horst D, Reiche JA, Engel J, Kirchner T and Jung A: LEF-1 and TCF4 expression correlate inversely with survival in colorectal cancer. J Transl Med 8: 123, 2010.
35. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E and Ambros V: Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 5: R13, 2004.
36. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R and Rajewsky N: Widespread changes in protein synthesis induced by microRNAs. Nature 455: 58-63, 2008.
37. Gao C, Zhang Z, Liu W, Xiao S, Gu W and Lu H: Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer 116: 41-49, 2010.
38. Marracci GH, Jones RE, McKeon GP and Bourdette DN: Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 131: 104-114, 2002.
39. Singh S, Narang AS and Mahato RI: Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res 28: 2996-3015, 2011.
40. Grimm D, Streetz KL, Jopling CL, et al: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541, 2006.
41. Narayan G, Goparaju C, Arias-Pulido H, et al: Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer 5: 16, 2006.